A Multi-center, Prospective Study Evaluating the Rate of Inhibitor Recurrence Following Successful ITI in Patients Receiving Ongoing Once Per Weekly Factor VIII Therapy Along With Emicizumab and in Patients Who Discontinue FVIII Therapy and Are on Emicizumab for Prophylaxis
Latest Information Update: 09 Oct 2023
At a glance
- Drugs Emicizumab (Primary) ; Factor VIII
- Indications Haemophilia A
- Focus Therapeutic Use
- Acronyms PRIORITY
- 28 Feb 2023 Planned End Date changed from 21 Sep 2022 to 20 Apr 2025.
- 28 Feb 2023 Planned primary completion date changed from 21 Sep 2022 to 20 Sep 2024.
- 12 Nov 2020 New trial record